Sabrina Sgambatti1, Ruth Minamisava2, Ana Luiza Bierrenbach3, Cristiana Maria Toscano3, Maria Aparecida Vieira4, Gabriela Policena3, Ana Lucia Andrade3. 1. Department of Tropical Medicine and Dermatology, Federal University of Goiás, Goiânia, Goiás, Brazil; Department of Medicine, Pontifical Catholic University of Goiás, Goiânia, Goiás, Brazil. Electronic address: sasgambatti@gmail.com. 2. Faculty of Nursing, Federal University of Goiás, Goiânia, Goiás, Brazil. 3. Department of Community Health, Federal University of Goiás, Goiânia, Goiás, Brazil. 4. Department of Nursing, Pontifical Catholic University of Goiás, Goiânia, Goiás, Brazil.
Abstract
BACKGROUND: In Brazil, 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in 2010 in the childhood routine immunization program. We used primary data to evaluate the effect of PCV10 on the reduction of hospital admissions due to community-acquired pneumonia (CAP). METHODS: Active population-based surveillance studies on pneumonia hospitalizations in children aged <36 months were conducted before and after PCV10 introduction in Central Brazil. The surveillances comprised all 17 pediatric hospitals of the study area, which provide assistance for public and private health insurances. Linear regression was performed to detect any trend in pneumonia monthly rates previously to vaccine introduction. PCV10 post-vaccination impact (Nov/2011 to Oct/2013) on clinical and X-Ray confirmed pneumonia was estimated as the relative and the absolute reduction (prevented burden) in pneumonia admission rates, taking as baseline the pre-vaccination period (May/2007 to Apr/2009). RESULTS: Overall, males presented higher rates of pneumonia hospitalization, compared to females. The relative rate reduction for clinical and X-Ray confirmed pneumonia was 13.1%, and 25.4%, respectively for children aged 2-23 months. The highest prevented burden was observed in age-groups 2-11 months, respectively 853/100,000 (from 6788/100,000 to 5935/100,000), and 729/100,000 (from 2871/100,000 to 2142/100,000), for clinical and X-Ray confirmed pneumonia. CONCLUSIONS: This study provides evidence for the impact of PCV10 in clinical and X-Ray confirmed pneumonia in routine vaccination program in Brazil, after 3 years of vaccine introduction. Extended follow-up studies should confirm the benefit of vaccination through herd effect given the high burden of pneumonia in our setting.
BACKGROUND: In Brazil, 10-valent pneumococcal conjugate vaccine (PCV10) was introduced in 2010 in the childhood routine immunization program. We used primary data to evaluate the effect of PCV10 on the reduction of hospital admissions due to community-acquired pneumonia (CAP). METHODS: Active population-based surveillance studies on pneumonia hospitalizations in children aged <36 months were conducted before and after PCV10 introduction in Central Brazil. The surveillances comprised all 17 pediatric hospitals of the study area, which provide assistance for public and private health insurances. Linear regression was performed to detect any trend in pneumonia monthly rates previously to vaccine introduction. PCV10 post-vaccination impact (Nov/2011 to Oct/2013) on clinical and X-Ray confirmed pneumonia was estimated as the relative and the absolute reduction (prevented burden) in pneumonia admission rates, taking as baseline the pre-vaccination period (May/2007 to Apr/2009). RESULTS: Overall, males presented higher rates of pneumonia hospitalization, compared to females. The relative rate reduction for clinical and X-Ray confirmed pneumonia was 13.1%, and 25.4%, respectively for children aged 2-23 months. The highest prevented burden was observed in age-groups 2-11 months, respectively 853/100,000 (from 6788/100,000 to 5935/100,000), and 729/100,000 (from 2871/100,000 to 2142/100,000), for clinical and X-Ray confirmed pneumonia. CONCLUSIONS: This study provides evidence for the impact of PCV10 in clinical and X-Ray confirmed pneumonia in routine vaccination program in Brazil, after 3 years of vaccine introduction. Extended follow-up studies should confirm the benefit of vaccination through herd effect given the high burden of pneumonia in our setting.
Authors: Christian A W Bruhn; Cynthia Schuck-Paim; Esra Kürüm; Robert J Taylor; Lone Simonsen; Daniel M Weinberger Journal: Epidemiology Date: 2017-03 Impact factor: 4.822
Authors: Christian A W Bruhn; Stephen Hetterich; Cynthia Schuck-Paim; Esra Kürüm; Robert J Taylor; Roger Lustig; Eugene D Shapiro; Joshua L Warren; Lone Simonsen; Daniel M Weinberger Journal: Proc Natl Acad Sci U S A Date: 2017-02-01 Impact factor: 11.205
Authors: Ana L Sartori; Ruth Minamisava; Ana L Bierrenbach; Cristiana M Toscano; Eliane T Afonso; Otaliba L Morais-Neto; José L F Antunes; Elier B Cristo; Ana Lucia Andrade Journal: PLoS One Date: 2017-06-08 Impact factor: 3.240
Authors: Jacek Wysocki; Jerzy Brzostek; Ryszard Konior; Falko G Panzer; Nancy A François; Sudheer M Ravula; Devayani A Kolhe; Yue Song; Ilse Dieussaert; Lode Schuerman; Dorota Borys Journal: Hum Vaccin Immunother Date: 2016-10-13 Impact factor: 3.452
Authors: Lucia Helena de Oliveira; Luiz Antonio B Camacho; Evandro S F Coutinho; Martha S Martinez-Silveira; Ana Flavia Carvalho; Cuauhtemoc Ruiz-Matus; Cristiana M Toscano Journal: PLoS One Date: 2016-12-12 Impact factor: 3.240
Authors: Sheila Elke Araujo Nunes; Ruth Minamisava; Maria Aparecida da Silva Vieira; Alexander Itria; Vicente Porfirio Pessoa; Ana Lúcia Sampaio Sgambatti de Andrade; Cristiana Maria Toscano Journal: Einstein (Sao Paulo) Date: 2017 Apr-Jun
Authors: Ana Lucia Andrade; Eliane T Afonso; Ruth Minamisava; Ana Luiza Bierrenbach; Elier B Cristo; Otaliba L Morais-Neto; Gabriela M Policena; Carla M A S Domingues; Cristiana M Toscano Journal: PLoS One Date: 2017-09-07 Impact factor: 3.240